DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00993720

CompletedPhase 2, PHASE3

Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Type 1 diabetes

Key I/E criterion

•BMI 18-27

Primary endpoint

•Insulin-dose

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00993720
Org study ID2009-001930-80

Timeline

Milestones

Study first posted2009-10-12estimated
Last update posted2011-01-21estimated
Study start2009-10 (month precision)
Primary completion2010-10actual (month precision)
Study completion2010-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•age 18-50y,
•BMI 18-27,
•caucasian origin,
•type 1 diabetes diagnosed between age 5 and age 40,
•no known diabetes complications or cardiovascular diseases,
•no medication known to influence glucose homeostasis,
•no pregnancy

Exclusion criteria

•diabetes complications,
•autonomous nerve dysfunction,
•anaemia,
•HbA1c < 8.5% at screening,
•estimated by the investigator to be incapable of completing the trial.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Glycemic / diabetes
1
Safety / tolerability / PK
1
Other clinical outcomes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

24-hours glucose profiles with and without treatment of Victoza

Time frame:three days

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

risk of hypoglycemia during physical activity with and without Victoza

Time frame:one day

Documented hypoglycemia

descriptive, event

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

gastric emptying rate during hypoglycemia with and without Victoza

Time frame:one day

descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

insulin-dose

Time frame:4 weeks

descriptive

Secondary/protocol endpoint/low confidence

weight change from baseline, change in fructosamine from baseline

Time frame:four weeks

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.